NASDAQ:NEUP

Neuphoria Therapeutics Q2 2026 Earnings Results & Report

Neuphoria Therapeutics logo
$2.29 +0.02 (+0.88%)
Closing price 03:59 PM Eastern
Extended Trading
$2.28 -0.01 (-0.44%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuphoria Therapeutics missed analyst earnings expectations in its Q2 2026 results, released February 17, 2026. The company reported EPS of -$0.77 versus the -$0.56 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Neuphoria Therapeutics EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.21
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Neuphoria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Neuphoria Therapeutics Q2 2026 Earnings FAQ

Neuphoria Therapeutics (NASDAQ:NEUP) reported earnings of -$0.77 per share for Q2 2026, missing the consensus estimate of -$0.56. The report was announced on Tuesday, February 17, 2026.

Neuphoria Therapeutics Earnings Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Neuphoria Therapeutics Inc Ordinary Shares NEUP
Neuphoria Therapeutics Inc (NEUP)
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions.

The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies.

Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

View Neuphoria Therapeutics Profile